One-staged brachial-basilic vein transposition versus arm straight arteriovenous graft for hemodialysis
Vascular · 2025
DOI: 10.1177/17085381241245068 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Vascular, 2025. Verfasst von Kanoklada Srikuea und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular Surgery, Department of Surgery, Faculty of Medicine, Thammasat University Hospital, Thammasat University, Pathum Thani, Thailand. Hauptthemen laut MEDLINE: Renal Dialysis, Arteriovenous Shunt, Surgical, Upper Extremity, Veins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Objectives
After forearm and arm cephalic veins are no longer available as options, the choices of arm vascular access between one-staged brachial-basilic vein transposition (BBAVF) and arm straight arteriovenous graft (AS-AVG) for hemodialysis are controversial. This study aims to compare outcomes between groups.
Methods
All one-staged BBAVF and AS-AVG from August 2014 to December 2019 were reviewed. In cases of suitable basilic vein of 3 mm or more present from cubital crease to axilla, one-staged BBAVF was preferred. AS-AVG was performed for patients who need timely functioning access or have no suitable basilic vein.
Results
Twenty-eight one-staged BBAVF and 74 AS-AVG were included. Baseline characteristics were not significantly different, except AS-AVG had less previous ipsilateral access (9% vs 39%; p < .001). Postoperative complications were not different. With six loss follow-ups (3 in BBAVF and 3 in AS-AVG), 24 (96%) and 64 (90%) matured after one-staged BBAVF and AS-AVG, respectively ( p = .676). BBAVF took about 30 days (95% CI: 10, 51) longer time to first successful cannulation. Primary patency was significantly better for one-staged BBAVF (hazard ratio (HR) of 3.0 (95%CI: 1.2, 7.7)), whereas secondary patency was not different. The total access failure (i.e. failure to mature combined with any thrombosis or intervention to maintain patency) significantly favored BBAVF (HR 2.7 (95%CI: 1.1, 6.6)).
Conclusions
Provided a suitable arm basilic vein is available, one-staged BBAVF is preferred over AS-AVG when forearm AVF, forearm AVG, and arm cephalic veins are out. However, it requires a longer time to start cannulating than AS-AVG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Vascular Surgery, Department of Surgery, Faculty of Medicine, Thammasat University Hospital, Thammasat University, Pathum Thani, Thailand.
- Department of Surgery, Somdejprasangkharach XVII Hospital, Suphanburi, Thailand.
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Department of Cardiac, Thoracic and Vascular Surgery, National University Heart System, Singapore.
- Environmental - Occupational Health Sciences and Non-Communicable Diseases Research Group, Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
- Clinical Surgical Research Center, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
ORCID-Profile: Boonying Siribumrungwong
Zitieren
APA
Srikuea, K., Prajumsukh, K., Orrapin, S., Benyakorn, T., Ho, P., Rerkasem, K., & Siribumrungwong, B. (2025). One-staged brachial-basilic vein transposition versus arm straight arteriovenous graft for hemodialysis. Vascular. https://doi.org/10.1177/17085381241245068
Vancouver
Srikuea K, Prajumsukh K, Orrapin S, Benyakorn T, Ho P, Rerkasem K, et al. One-staged brachial-basilic vein transposition versus arm straight arteriovenous graft for hemodialysis. Vascular. 2025. doi:10.1177/17085381241245068
BibTeX
@article{Srikuea2025,
author = {Srikuea, Kanoklada and Prajumsukh, Kesanan and Orrapin, Saritphat and Benyakorn, Thoetphum and Ho, Pei and Rerkasem, Kittipan and Siribumrungwong, Boonying},
title = {One-staged brachial-basilic vein transposition versus arm straight arteriovenous graft for hemodialysis},
journal = {Vascular},
year = {2025},
doi = {10.1177/17085381241245068}
}
EUVIMED